Axogen is transforming from a niche tissue supplier into a comprehensive nerve care platform, underp

Canaccord Genuity analyst Caitlin Roberts maintains Axogen (NASDAQ:AXGN) with a Buy and raises th

Citizens analyst David Turkaly maintains Axogen (NASDAQ:AXGN) with a Market Outperform and raises

HC Wainwright & Co. analyst Yi Chen maintains Axogen (NASDAQ:AXGN) with a Buy and raises the

AxoGen, Inc. (NASDAQ: AXGN - Get Free Report)'s stock price gapped down prior to trading on Wednesda

Axogen, Inc. (AXGN) Q2 2026 Earnings Call Transcript

AxoGen NASDAQ: AXGN reported second-quarter 2026 revenue of $69.7 million, up 23.1% from a year earl

AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estim

Nerve Trace is a near-infrared fluorescence imaging technology designed to provide direct, real-time

/PRNewswire/ -- Trace Biosciences, Inc., a clinical-stage biotechnology company developing nerve-tar

Axogen (NASDAQ:AXGN) reported quarterly earnings of $0.12 per share which missed the analyst consens

ALACHUA, Fla. and TAMPA, Fla.

ALACHUA, Fla. and TAMPA, Fla. , July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a glo

AxoGen, Stock Of the Day, is flashing a buy signal. Ten out of 10 analysts are bullish about AxoGen

AxoGen NASDAQ: AXGN President and CEO Michael Dale said the company's growth strategy remains center

Axogen, Inc. (AXGN) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks T

ALACHUA, Fla. and TAMPA, Fla.

Citizens analyst David Turkaly maintains Axogen (NASDAQ:AXGN) with a Market Outperform and raises

Wells Fargo analyst Larry Biegelsen maintains Axogen (NASDAQ:AXGN) with a Overweight and raises t

HC Wainwright & Co. analyst Yi Chen maintains Axogen (NASDAQ:AXGN) with a Buy and raises the

Axogen, Inc. (AXGN) Q1 2026 Earnings Call Transcript

U.S. stocks mixed, Nasdaq down 200 points. CommVault shares up 9.9% after beating earnings estimate

AxoGen (AXGN) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estim

Axogen (NASDAQ: AXGN) FY2026 Revenue expected to be at least $270.000M vs $266.219M EstAxogen (NASDA

Axogen (NASDAQ:AXGN) reported quarterly earnings of $0.07 per share which met the analyst consensus

ALACHUA, Fla. and TAMPA, Fla.

This healthcare firm develops nerve repair solutions for hospitals and specialists in the U.S. and s

Lake Street analyst Frank Takkinen maintains Axogen (NASDAQ:AXGN) with a Buy and raises the price

AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat

AxoGen (AXGN) witnessed a jump in share price last session on above-average trading volume. The late

ALACHUA, Fla. and TAMPA, Fla.

Citizens analyst David Turkaly maintains Axogen (NASDAQ:AXGN) with a Market Outperform and raises

2026 Financial GuidanceWe expect 2026 revenue growth to be at least 18%, or $265.7 million, for the

Axogen (NASDAQ:AXGN) reported quarterly earnings of $0.07 per share which missed the analyst consens

Wells Fargo analyst Larry Biegelsen initiates coverage on Axogen (NASDAQ:AXGN) with a Overweight

Axogen stock fell Thursday with a session volume of 1.92 million, priced its upsized underwritten pu

Common StockPreferred StockDebt SecuritiesWarrants  We may, from time to time, offer and sell any co

Axogen (NASDAQ:AXGN) raises FY2025 sales outlook from $222.800 million to $225.200 million vs $223.3